Novartis Aims To Fly High In Kidney Disease With Chinook Buy
Paying $3.2bn Upfront For Two Phase III IgAN Drugs
Buying Chinook will add a pair of late-stage programs to Novartis's IgAN portfolio which is currently headed by iptacopan but the proposed deal could attract the attention of the FTC.
